FBR Capital announced AmerisourceBergen (NYSE:ABC), bumping up its stock price target to $90.00 today
- Updated: September 18, 2016
Reporting a possible upside of 0.01%, FBR Capital upped the target price of AmerisourceBergen (NYSE:ABC) to $90.
Just yesterday AmerisourceBergen (NYSE:ABC) traded 0.11% lower at $89.43. AmerisourceBergen’s 50-day average is $87.56 and its two hundred day moving average is $83.67. The last close is up 0.53% from the two hundred day moving average, compared with the S&P 500 which has fallen -0.01% over the same time. Trade volume was was up over the average, with 3,459,904 shares of ABC changing hands over the typical 2,078,810 shares..
See Chart Below:
With a total market value of $0.0, AmerisourceBergen has a PE of 11 with a one-year low of $73.31 and a one-year high of $108.18.
In addition to FBR Capital reporting it’s target price, a total of 15 brokers have released a ratings update on the company. The consensus target price is $85.40 with four firms rating the stock a strong buy, two analysts rating the company a buy, 12 analyts rating the stock a hold, 0 rating the stock to underperform, and finally 0 firmsrating the stock as sell.
Brief Synopsis About AmerisourceBergen (NYSE:ABC)
AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company operates through two segments: Pharmaceutical Distribution and Other. The Company also provides data and other services to its manufacturing customers. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. The Company provides pharmacy services to certain specialty drug patients. Additionally, the Company offers healthcare providers and pharmaceutical manufacturers with services, including reimbursement and pharmaceutical consulting services, logistics services, inventory management, and pharmacy automation and pharmacy management. The Company has a distribution facility network totaling approximately 30 distribution facilities in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.